Thromb Haemost 1971; 26(02): 411-413
DOI: 10.1055/s-0038-1653691
Vorläufige Mitteilungen – Preliminary Reports – Communications Préliminaires
Schattauer GmbH

“Angiokinase” - Molecular Weights of Proteins Representing a Perivascular Plasminogen Activator

W Auerswald
1   Department of Physiology (Director: Prof. Dr. W. Auerswald), School of Medicine, University of Vienna, Austria
,
B Binder
1   Department of Physiology (Director: Prof. Dr. W. Auerswald), School of Medicine, University of Vienna, Austria
,
W Doleschel
1   Department of Physiology (Director: Prof. Dr. W. Auerswald), School of Medicine, University of Vienna, Austria
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Summary

By means of gel filtration (Sephadex G-150) of precipitates originating from human cadaver vessel perfusates the molecular weights of a perivascular plasminogen activator “angiokinase” were determined. Maximum angiokinase activity was found at the molecular weight 61,000, high activities at 30,500 and 120,000, and traces of activity at 15,000, 45,700, and 76,000. Presumably angiokinase is the product of polymerization of a basic unit (mol. weight 30,500) or its subunit (mol. weight 15,000).

 
  • References

  • 1 Astrup T. Tissue activators of plasminogen. Fed. Proc 25: 42 1966;
  • 2 Auerswald W, Doleschel W. Appearance of aggregates and subunits of urokinase in human urine concentrates. Abstr. 2nd Internat. Biophysics Congr. of the IOPAB, B 1 (a) 1.1.4. Nr. 62, Vienna Sept 5-9 1966;
  • 3 Auerswald W, Doleschel W, Zweymüller E. Uroprotein excretion in neonates and infants. Z. Kinderheilk 109: 262 1971;
  • 4 Bernik M. B, Kwaan H. C. Plasminogen activator activity in cultures from human tissues. J. clin. Invest 48: 1740 1960;
  • 5 Binder B, Mlczoch H, Zarrabi Z. A method for extraction of perivascular plasminogen activator from fresh human cadavers. (In press.)
  • 6 Doleschel W, Auerswald W. Determination of the molecular weights of uroprotein fractions with urokinase activity by means of molecular sieving. Med. Pharmacol, exp 16: 225 1967;
  • 7 Hiemeyer V. The fibrinolytic activity of blood derived from vessel wall. Angiologica 05: 95 1968;
  • 8 Holemans R. Enhancement of fibrinolysis in the dog by injection of vasoactive drugs. Amer. J. Physiol 208: 511 1965;
  • 9 Holemans R, Mlynarczylc E. J, Mann L. S, Poiesz B. J. Differentiation of blood and tissue activator of plasminogen. Fed. Proc 26: 647 1967;
  • 10 Isacson S, Nilsson I. M. The kidneys and the fibrinolytic activity in the blood. Thrombos. Diathes. haemorrh. (Stuttg) 22: 211 1969;
  • 11 Karaca M, Nilsson I. M. Fibrinolytic activity in hemiplegic patients. Acta med. scand 189: 325 1971;
  • 12 Kaulla K. N, WasantaprueJc S. Extraction of plasminogen activator from canine vascular segments. Exp. Biol. Med 132: 830 1969;
  • 13 Pandolfi M. Persistence of fibrinolytic activity in fragments of human veins cultured in vitro. Thrombos. Diathes. haemorrh. (Stuttg) 24: 43 1970;
  • 14 Szczepanslci M, Nilsson I. M. The fibrinolytic activity in tissues during the peripheral venous occlusion in rat. Thrombos. Diathes. haemorrh. (Stuttg) 24: 522 1970;